Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6121206 | 0.79 | GRIN2D (0.33) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL20781805 | 0.78 | ALDH1A1 (0.32) | HSD11B1 | |
| SCHEMBL24865146 | 0.78 | GAA (0.31) | — | |
| SCHEMBL13599980 | 0.77 | — | — | |
| SCHEMBL20147958 | 0.74 | GRIN2D (0.38) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL19504477 | 0.73 | GRIN2D (0.41) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL23666996 | 0.72 | — | — | |
| SCHEMBL10205023 | 0.71 | GRIN2D (0.39) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL16662245 | 0.71 | GRIN2D (0.39) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL17711700 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | GRIN2D 3129/4885GRIN3B 1716/4885CHRM2 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.